Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
UK Home Asking Prices Rise for First Time Since May 
Trump Plans Federal AI Force and AI Czar 
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash 
Meta Partners With Shopify to Bring Shop Pay Checkout to Muse AI 
Vietnam, US Trade Deal Could Be Signed Soon, To Lam Says 
US, Japan and South Korea Back Taiwan Ahead of Trump-Xi Summit 
Volkswagen Shares Slide After 2026 Profit Outlook Cut 
Trump Bans CNN, MS NOW and Politico From White House 
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap 
France Debt-to-GDP Ratio Seen Hitting Record 119.3% in 2026 
S&P 500 Historically Rallies After Midterm Elections, UBS Says 
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Vietnam Stocks Join FTSE Emerging Market Indexes, Unlocking Billions in Foreign Investment 
U.S. Dollar Hits Eight-Week High After Fed Rate Hike 
Gold Prices Hold Steady Ahead of Trump-Xi Summit, Middle East Risks 
Add as a preferred source on Google
Celltrion announced that its COVID-19 test kit called DiaTrust has been given conditional approval by South Korea’s drug safety board. The biopharmaceutical company headquartered in Incheon shared the news on Monday, April 3.
The new coronavirus test kit
The Korea Herald reported that DiaTrust was jointly developed by Celltrion and Humasis, an R&D company based in S. Korea as well. The two sides made this antigen test kit that is said to be capable of detecting the newest COVID-19 variants that originated in Brazil and the U.K.
The rapid test kit can show results in as short as 15 minutes. It will identify the particular antigens of coronavirus that are present in the specimen collected from a person through a sterile nasal swab. Celltrion explained that what sets this kit apart from the other of its kind is that it uses a dual antigen method that can spot both N and S antigens.
“Celltrion will speed up its supply of COVID-19 test kit in the domestic market,” a company official stated. “The firm will submit additional clinical data concerning the test kit to the Ministry of Food and Drug Safety within three months.”
The biopharma company is expecting a surge in global demand for the DiaTrust COVID-19 test kit in the near future. In fact, in the U.S., the kit already received emergency use approval from the Food and Drug Administration (FDA). In April, the agency gave its authorization based on the clinical trial results that Celltrion submitted, and it is now reviewing additional clinical data.
Self-test kit to be marketed after gaining FDA nod
Celltrion was granted conditional approval for DiaTrust last week and to get its formal authorization from S. Korea’s Ministry of Food and Drug Safety. It needs to submit more clinical data within three months, as per the Korea Bio Medical Review.
It was added that the company is planning to supply the COVID-19 test kits via its subsidiary firm, Celltrion Pharm. It is also looking at other distribution outlets such as iMarket Korea.
Meanwhile, Celltrion’s new DiaTrust COVID-19 Ag home test kit was said to have shown results with high accuracy. However, it pointed out that suspected coronavirus patients with an obvious epidemiological connection to infection should get PCR tests at authorized screening centers set up by health authorities because the kits are just a supportive tool.
